Admedus TAVR project on track with new IP applications
24, October, 2017
Admedus Ltd today announced that it has submitted IP applications relating to the development of a new Transcatheter Aortic Valve Replacement (TAVR) device. Read the full ASX statement here.
Investor webinar 5 September 2017
1, September, 2017
Admedus Limited (ASX: AHZ) held an investor webinar on 5 September, 2017 to discuss the results of the Company’s Preliminary Final Report (Appendix 4E) for the year ended 30 June 2017. Admedus CEO Wayne Paterson will provide a review of the Company’s year-end performance as well as operational and business highlights.
Admedus announces exclusive supply agreement with 4C Medical
31, August, 2017
Admedus Limited is pleased to announce that it has entered an exclusive supply agreement with 4C Medical Technologies, Inc. (4C Medical), a Minnesota-based developer of minimally invasive therapies for structural heart disease. Read more here.
Admedus attracts keen interest from surgeons at symposium
11, July, 2017
Professor Leon Neethling recently attended the 53rd Annual Meeting of the Japanese Society of Paediatric Cardiology and Cardiac Surgery, in Hamamatsu, where he presented at a lunch symposium to more than 180 congenital surgeons from Japan, Vietnam, Philippines, Malaysia, Taiwan and Korea about our ADAPT products as part of the 13th Japan-China-Korea Paediatric Heart Forum.
CardioCel: 8 years on and still free from calcification
23, August, 2016
CardioCel® is proving to be one of the biggest game changers in the congenital heart defect repairs and reconstructions space, offering significant long-term benefits to patients. While other tissue patches can calcify up to 18 months post implantation in paediatric patients, the latest follow up data released by Admedus shows no evidence of calcification using […]
Using the ADAPT engineering process to create durable tissue scaffolds
8, July, 2016
Admedus is an Australian-based healthcare company leading the world in regenerative medicine and tissue engineering research. Using its proprietary ADAPT® tissue engineering technology, Admedus can transform xenograft (animal) tissue into durable bio-scaffolds that can be used for soft tissue repair within patients. The medical technology was first brought to Australia over 20 years ago by […]
Admedus a major distributor of infusion solutions
10, June, 2016
Many people would have heard about the great work Admedus is doing in the field of tissue engineering and immunotherapies, but fewer people would know that Admedus is also a major distributor of infusion solutions (intravenous products and infusion pumps) to hospitals in Australia and New Zealand. The highly successful infusion portfolio has been part […]
A day with Europe’s leading cardiovascular surgeons
5, May, 2016
In April, I had the privilege of spending the day with over forty of Europe’s leading cardiovascular surgeons. The purpose – an Admedus workshop to discuss the use of CardioCel to reconstruct heart valves and its potential in the future treatment of heart valve disease. Held in Amsterdam, the experts meeting shed light on the critical issues and […]